BioCryst Pharmaceuticals (MEX:BCRX) Beneish M-Score : 255.80 (As of Apr. 06, 2025)

View and export this data going back to 2019. Start your Free Trial

What is BioCryst Pharmaceuticals Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 255.8 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for BioCryst Pharmaceuticals's Beneish M-Score or its related term are showing as below:

MEX:BCRX' s Beneish M-Score Range Over the Past 10 Years
Min: -4.59 Med: -1.8 Max: 255.8
Current: 255.8

During the past 13 years, the highest Beneish M-Score of BioCryst Pharmaceuticals was 255.80. The lowest was -4.59. And the median was -1.80.

BioCryst Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for BioCryst Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCryst Pharmaceuticals Beneish M-Score Chart

BioCryst Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Beneish M-Score

Get a 7-Day Free Trial

-4.59

3.35

-1.52

-3.66

255.80

BioCryst Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Beneish M-Score	Get a 7-Day Free Trial															-3.66	-1.92	9.91	-	255.80

Competitive Comparison of BioCryst Pharmaceuticals's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioCryst Pharmaceuticals's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Beneish M-Score falls into.

Save Embed

;

Save Embed

;

BioCryst Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of BioCryst Pharmaceuticals for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 * 1.1418

0.528 * 1.0151

0.404 * 640.2258

0.892 * 1.494

0.115 * 1.391

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 * 0.9135

4.679 * -0.076168

0.327 * 1.0475

256.03

This Year (Dec24) TTM:

Last Year (Dec23) TTM:

Total Receivables was MXN1,649 Mil.
Revenue was 2743.234 + 2305.439 + 2002.974 + 1539.485 = MXN8,591 Mil.
Gross Profit was 2615.367 + 2241.878 + 1971.206 + 1516.383 = MXN8,345 Mil.
Total Current Assets was MXN8,800 Mil.
Total Assets was MXN10,228 Mil.
Property, Plant and Equipment(Net PPE) was MXN413 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN24 Mil.
Selling, General, & Admin. Expense(SGA) was MXN5,066 Mil.
Total Current Liabilities was MXN3,345 Mil.
Long-Term Debt & Capital Lease Obligation was MXN16,809 Mil.
Net Income was -558.828 + -276.314 + -232.189 + -587.159 = MXN-1,654 Mil.
Non Operating Income was -12.597 + 1.93 + -1.539 + -0.846 = MXN-13 Mil.
Cash Flow from Operations was -108.721 + 162.347 + -25.062 + -890.953 = MXN-862 Mil.

Total Receivables was MXN967 Mil.
Revenue was 1585.412 + 1510.95 + 1414.217 + 1239.723 = MXN5,750 Mil.
Gross Profit was 1557.625 + 1491.162 + 1397.931 + 1222.816 = MXN5,670 Mil.
Total Current Assets was MXN8,419 Mil.
Total Assets was MXN8,775 Mil.
Property, Plant and Equipment(Net PPE) was MXN355 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN29 Mil.
Selling, General, & Admin. Expense(SGA) was MXN3,712 Mil.
Total Current Liabilities was MXN2,546 Mil.
Long-Term Debt & Capital Lease Obligation was MXN13,961 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(1649.039 / 8591.132)	/	(966.683 / 5750.302)
	=	0.191947	/	0.16811
	=	1.1418

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(5669.534 / 5750.302)	/	(8344.834 / 8591.132)
	=	0.985954	/	0.971331
	=	1.0151

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (8800.438 + 412.63) / 10228.052)	/	(1 - (8418.65 + 354.999) / 8775.007)
	=	0.099235	/	0.000155
	=	640.2258

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	8591.132	/	5750.302
	=	1.494

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(28.774 / (28.774 + 354.999))	/	(23.508 / (23.508 + 412.63))
	=	0.074977	/	0.0539
	=	1.391

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(5066.448 / 8591.132)	/	(3712.158 / 5750.302)
	=	0.58973	/	0.645559
	=	0.9135

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((16809.069 + 3344.921) / 10228.052)	/	((13961.319 + 2545.934) / 8775.007)
	=	1.970462	/	1.881167
	=	1.0475

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-1654.49 - -13.052	-	-862.389)	/	10228.052
	=	-0.076168

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

BioCryst Pharmaceuticals has a M-score of 256.03 signals that the company is likely to be a manipulator.

BioCryst Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

BioCryst Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioCryst Pharmaceuticals Inc (MEX:BCRX) » Definitions » Beneish M-Score

Comparable Companies

Traded in Other Exchanges

BCRX:USA BO1:Germany BO1:Germany

Address

4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703

Website

https://www.biocryst.com

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.